Featured Research

from universities, journals, and other organizations

Drug Brings Relief For Many IBS Patients Who Experience Constipation

Date:
May 20, 2008
Source:
University of Michigan Health System
Summary:
Many patients may soon find relief from the bloating, cramping, abdominal pain and constipation associated with irritable bowel syndrome. AMITIZA was just approved by the FDA for use in women with IBS plus constipation, thanks to new research that demonstrated the safety and efficacy of the drug for treatment of IBS-C.

Many patients may soon find relief from the bloating, cramping, abdominal pain and constipation associated with irritable bowel syndrome, or IBS.

Lubiprostone, known by the brand name AMITIZA®, was just approved by the U.S. Food and Drug Administration for use in women with IBS plus constipation, thanks in part to University of Michigan Health System research that demonstrated the safety and efficacy of the drug for treatment of IBS-C.

Led by U-M gastroenterologist William D. Chey, M.D., the studies show that lubiprostone significantly improves all of the symptoms associated with IBS-C in many women.

Results from these studies will be presented on May 18 and May 19 at Digestive Diseases Week in San Diego.

"We found that individuals who were treated with AMITIZA were nearly twice as likely to experience improvement in their IBS symptoms compared to individuals who were treated with placebo," says Chey, director of the Gastrointestinal Physiology Laboratory and professor of internal medicine at the U-M Medical School. "Right now, it is the only FDA-approved treatment available that addresses the entire clinical spectrum of symptoms related to IBS-C."

IBS, an often painful disorder of the lower intestine, affects between 10 to 15 percent of the U.S. population.

While IBS is the second-leading cause of work absenteeism behind the common cold, Chey says fewer than half of patients with IBS seek medical treatment. And, he says, most over-the-counter medicines commonly used to treat symptoms -- fiber, laxatives and stool stimulants -- don't address the bloating and pain associated with IBS.

Most patients with IBS tend to fall into two categories: IBS-C or IBS with diarrhea. IBS-C is more common among older adults, while IBS-D tends to be seen more in younger patients.

Since the majority of patients with IBS are women, studies involving IBS tend to be made up of predominately female participants -- more than 80 percent in most cases, Chey estimates.

"Although AMITIZA is only approved for use in women with IBS-C, it doesn't mean that the drug doesn't work for men. Unfortunately, we just haven't had enough men represented in these studies to make a firm decision on treatment using this drug," notes Chey.

The supplemental New Drug Application for AMITIZA -- which also is approved by the FDA for treatment of chronic idiopathic constipation -- was based on two phase III, multi-center trials involving 1,154 participants. These trials compared lubiprostone versus a placebo during the course of 12 weeks. Each participant kept an electronic diary to report weekly outcomes of IBS-C symptoms.

After one week, 20 percent of the lubiprostone participants reported moderate to significant relief of symptoms. By week four, 32 percent said they experienced relief of global IBS-C symptoms -- abdominal pain, bloating, constipation severity and straining during bowel movements. Lubiprostone also improved stool consistency.

Additionally, Chey will present findings at DDW from a follow-on study related to the two phase III trials. This 48-week study looked at the efficacy and safety of lubiprostone. Many of its 476 participants also took part in the phase III trials. For this study, however, participants all received lubiprostone; no placebos were given.

The study found that lubiprostone is effective and well tolerated in adults with IBS-C for up to one year. The spectrum of symptoms that constitute IBS-C, including abdominal pain and discomfort, bloating and constipation-related complaints, significantly improved during the 48-week treatment period. The most common treatment-related adverse events among the study groups were nausea and diarrhea.


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "Drug Brings Relief For Many IBS Patients Who Experience Constipation." ScienceDaily. ScienceDaily, 20 May 2008. <www.sciencedaily.com/releases/2008/05/080519083028.htm>.
University of Michigan Health System. (2008, May 20). Drug Brings Relief For Many IBS Patients Who Experience Constipation. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2008/05/080519083028.htm
University of Michigan Health System. "Drug Brings Relief For Many IBS Patients Who Experience Constipation." ScienceDaily. www.sciencedaily.com/releases/2008/05/080519083028.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) — Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) — A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) — Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) — President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins